PitchSend

Valo SPAC Presentation Deck

Valo is seeking to develop best-in-class compounds leveraging known or proven biology OPL-0001: PARP1 THERAPEUTIC HYPOTHESIS DESIGNING A CNS-PENETRANT PARP1 INHIBITOR OPL-0036810 OPL-0036820 OPL-0036367 OPL-0036368 OPL-0036819 OPL-0036330 OPL-0036811 OPL-0036847 OPL-0036908 OPL-0036909 OPL-0036805 OPL-0036405 OPL-0036892 DEL-003 Log([brain]/[plasma]) DEL-001 DEL-005 DEL-002 OPL-0036804 DEL-004 Comparator 1 Comparator 2 Comparator 3 Comparator 4 Comparator 5 Valo Creating a PARP1 inhibitor with central penetrance while preserving activity could enable treatment of brain metastasis and primary brain cancers¹ -1.4 Predicted in vivo biodistribution -1.2 Plasma Comparators Molecules -0.8 -0.6 [1] Reflects management's current expectations -0.4 Log([brain]/[plasma]) -0.2 0 Brain 0.2 0.4 OPL-0021: NAMPT THERAPEUTIC HYPOTHESIS Concentration RAT RETINA AND PLASMA DISTRIBUTION RATIO Comparator (20 mpk) Clinical-stage NAMPT asset 40,000 30,000 20,000 10,000 Preventing NAMPT inhibition in the retina while driving peripheral activity could create a next generation cancer therapeutic¹ 0 13x Plasma drug Retina drug conc(ng/mL) conc (ng/g) OPAL-0021 (10 mpk) Valo preclinical NAMPT compound Plasma drug conc (ng/mL) 174x Retina drug conc (ng/g) 2Q21 29

View entire presentation